Reversal of Aging of Human Cartilage, Restoring Youthfulness; the First of Its Kind Feat by Edogawa Hospital, Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005420/en/
Prof. Masatoshi Koshiba (Nobel Laureate; Sitting Rt.) who initiated the idea of restoring youthfulness of cells in the lab with Dr Masahiro Katoh (Sitting Lt; Chairman, Edogawa Hospital), who accomplished Prof. Koshiba’s wishes, helped by Dr Shojiro Katoh (Standing Rt; President, Edogawa Hospital), led team including Dr. Samuel JK Abraham (Standing Lt) (Photo: Business Wire)
Aging of human body, its organs, tissues and cells is irreversible and in the lab environments, aging is much faster than inside the body. However, EELS-TALC technology has disrupted this conventional belief by making tissues younger, through tissue engineering in a chemically synthesized polymer scaffold, under physical maneuver of orbital shaking in the lab, without genetic manipulation or animal derived products, thus paving way to solutions that, when similar environment is made available inside the body, such reversal of aging might be possible.
EELS TALC cultured chondrocytes have all ideal characteristics, worth recommending as the most suitable in ACI and MACI treatments:
(i) Yielding Hyaline cartilage native to articular joints:
(ii) Hyaluronic acid enrichment, ideal for better healing:
(iii) Enhanced miRNA140, a hall mark of healthy cartilage:
(iv) Chondroprogenitors, mesenchymal stem cells grown from damaged tissues:
(v) Pluripotency marker expression and tissue like growth:
(vi) Increased telomere length, proving youthfulness:
Presented at meetings of British Society of Developmental Biology - Genetics Society & British Society of Gerontology; 2021.
(vii) Lower SA-ß-Gal, p16, p21; confirming the reversal of aging:
(viii) Pre-clinical studies proving, success in vivo:
EELS-TALC method is safe as it does not involve genomic alterations, oncogenes, viruses, or complex growth factors. Now, Dr. Katoh is evaluating ideal transportation of tissues and cells between the hospital and the lab based on earlier reported OPTRACT method (https://doi.org/10.1007/s10529-021-03116-y) and additional safety parameters, supported by EELS, JBM Inc, GN Corporation and NCRM, India, before starting clinical studies.